Prostate-specific antigen-based screening for prostate cancer: Evidence, controversies and future perspectives
作者： Kazuto Ito
DOI: 10.1111/J.1442-2042.2009.02293.X
关键词:
摘要: The most recent epidemiological survey revealed that the mortality rate for prostate cancer in Japan has increased and been getting very close to USA, where it decreased since 1992. low exposure of prostate-specific antigen (PSA) screening high PSA USA may result completely deferent trends between two countries. Japanese Urological Association recommends PSA-based men at risk age 50 years or older general 45 with a family history within first generation relatives. fact sheet on should indicate reliable clinical research its demerits including false-negative false-positive test results biopsy, overdetection overtreatment. However, be explained public will clarified step by during screening, general, having more information (PSA level, pathological findings biopsy specimens, stage, etc.) can understand their current situation better than those no results, levels.
sci-hub.se 参考文章(43)
David Skarsgard, Jon Tonita, Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes & Control. ,vol. 11, pp. 79- 88 ,(2000) , 10.1023/A:1008965617078
G D Chisholm, R F Deane, G B McKelvie, C D Rennie, E L Gilliland, C P Chilton, M G Royle, N H Townell, J Breakey, S M Cresswell, J Glaholm, G M Sole, J J Bolger, M J Stower, M H Ashken, D A Tolley, F J Bramble, P A Jones, R A Styles, Moffat Lef., R W Glashan, Rhind, A Radley, G J Fellows, J Crowther, B Hafner, S Knight, E Thompson, J Smith, J Burrett, P B Clark, J Boreham, R Peto, L N Jurczyk, B A DeSousa, S Parish, Logie Jrc., Ross Rta., Cox, K Perry, T P Stephenson, K K Sethia, Turner Dtl., M Davies, Harrison Gsm., G F Carswell, Rogers Acn., M Lucas, M R Heal, V Boag, J Hetherington, D Kirk, Charlton Cac., Shepheard Bgf., N A Green, M F Smith, T B Hargreave, Moore Kth., R J Morgan, K N Bullock, Bevis Cra., J B Anderson, A L Stewart, Newling Dwk., B Richards, Grayson Cea., Gaches Cgc., P T Doyle, Robinson Mrg., S Sagar, R J Shearer, C M Evans, R A Jones, Wightman Jak., E R Coulton, J C Smith, M E French, C S Powell, Fernie Cgm., Orr Pgg., M Claridge, Gallegos Crr., G H Urwin, G M Watson, C Roberts, S Griffin, M B Rose, M Fordham, G S Watson, W T Lawrence, R Pollard, P H Smith, M J James, Grant Jbp., J P Ward, R R Hall, M Hehir, J L Williams, R W Thomson, L L Beynon, R J Luck, R Rampling, R S Adib, P English, A McGregor, C D Baumber, J W Blaxland, M H Devereux, R Clack, Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial BJUI. ,vol. 79, pp. 235- 246 ,(1997)
D.H. Brewster, L.A. Fraser, V. Harris, R.J. Black, Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJUI. ,vol. 85, pp. 463- 473 ,(2000) , 10.1046/J.1464-410X.2000.00487.X
Koji Okihara, Koji Kitamura, Koichi Okada, Kazuya Mikami, Osamu Ukimura, Tsuneharu Miki, Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. International Journal of Urology. ,vol. 15, pp. 156- 160 ,(2008) , 10.1111/J.1442-2042.2007.01957.X
A. Majeed, P. Babb, J. Jones, M. Quinn, Trends in prostate cancer incidence, mortality and survival in England and Wales 1971–1998 BJUI. ,vol. 85, pp. 1058- 1062 ,(2000) , 10.1046/J.1464-410X.2000.00661.X
Grace Lu-Yao, Peter C. Albertsen, Janet L. Stanford, Therese A. Stukel, Elizabeth Walker-Corkery, Michael J. Barry, Screening, Treatment, and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up Journal of General Internal Medicine. ,vol. 23, pp. 1809- 1814 ,(2008) , 10.1007/S11606-008-0785-8
Philip C Prorok, Gerald L Andriole, Robert S Bresalier, Saundra S Buys, David Chia, E David Crawford, Ronald Fogel, Edward P Gelmann, Fred Gilbert, Marsha A Hasson, Richard B Hayes, Christine Cole Johnson, Jack S Mandel, Albert Oberman, Barbara O'Brien, Martin M Oken, Sameer Rafla, Douglas Reding, Wilmer Rutt, Joel L Weissfeld, Lance Yokochi, John K Gohagan, FACE for the PLCO Project Team, Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial Controlled Clinical Trials. ,vol. 21, pp. 273- ,(2000) , 10.1016/S0197-2456(00)00098-2
Fernand Labrie, Bernard Candas, Andr� Dupont, Lionel Cusan, Jose-Luis Gomez, Raul E. Suburu, Pierre Diamond, Jacques L�vesque, Alain Belanger, Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. The Prostate. ,vol. 38, pp. 83- 91 ,(1999) , 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B
Kazuto Ito, Takumi Yamamoto, Mai Miyakubo, Hiroyuki Takechi, Masaru Ohi, Yasuhiro Shibata, Kazuhiro Suzuki, Lead Time of Prostate Cancer Detected in Population Based Screening for Prostate Cancer in Japan Journal of Urology. ,vol. 178, pp. 1258- 1264 ,(2007) , 10.1016/J.JURO.2007.05.144
P.N Post, P.J.M Kil, M.A Crommelin, R.F.M Schapers, J.-W.W Coebergh, Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands, 1971–1995 European Journal of Cancer. ,vol. 34, pp. 705- 709 ,(1998) , 10.1016/S0959-8049(97)10154-X